EP Patent

EP3544614A1 — Oral testosterone undecanoate therapy

Assigned to Lipocine Inc · Expires 2019-10-02 · 7y expired

What this patent protects

The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a testoste…

USPTO Abstract

The present disclosure provides methods and compositions for testosterone replacement therapy. The methods and compositions employ a fixed dose dosing regimen that does not require titration or dose adjustments and that can provide a therapeutically effective amount of a testosterone ester while avoiding unacceptably high testosterone levels.

Drugs covered by this patent

Patent Metadata

Patent number
EP3544614A1
Jurisdiction
EP
Classification
—
Expires
2019-10-02
Drug substance claim
No
Drug product claim
No
Assignee
Lipocine Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.